NCT03962543 2026-04-08ReNeuSpringWorks Therapeutics, Inc.Phase 2 Active not recruiting114 enrolled 25 charts 3 FDA
NCT02407405 2026-03-05MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform NeurofibromasNational Institutes of Health Clinical Center (CC)Phase 2 Active not recruiting36 enrolled